An interventional study of low-level laser/light therapy in Male Pattern Baldness and Female Pattern Baldness, sponsored by Awareable Technologies Inc. Status unknown at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-01.
Sponsored by Awareable Technologies Inc · Not applicable, Interventional, and Treatment
A total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat. Each treatment will be 30 min per session applied on every other day for 14 weeks.
609 studies on the registry are indexed under Alopecia; 131 are open to participants now.
This study's planned enrollment of 62 is above the median of 45 across 513 interventional studies indexed under Alopecia.
Browse Alopecia studies →This is the only study on the registry with Awareable Technologies Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
62 participants shall be enrolled
Device: low-level laser/light therapy
Participants will wear light therapy devices for 14 weeks
Hair Density
Individual participant's hair density will be measured at the end of 14 weeks and compared with the baseline density measure at the start of the treatment.
Time frame: 14 weeks
Hair Density
Mean hair density for the participants after 14 weeks will be compiled and compared with the mean density of the participants' at the start of the study to determine changes.
Time frame: 14 weeks
Hair Follicle Change
Both individual and all participants' follicles shall be analyzed to determine the percent of change in hair follicle anagen/telogen ratio
Time frame: 14 weeks
This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.